S. 79 · 118th Congress · Commerce

Interagency Patent Coordination and Improvement Act of 2023

Died in the Senate1.4k words Introduced Jan 25, 2023 · Latest action Mar 1, 2023

How far it has goneStopped at 3 of 6 · Died in the Senate
  1. IntroducedJan 25, 2023 Done
  2. CommitteeReported Mar 1, 2023 Done
  3. Senate floorDied Jan 3, 2025 Stopped here
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Congressional Research Service · summary of “Reported to Senate” version · Mar 1, 2023

Who lobbies on it

14 organizations · 115 filings · Q1 2023–Q4 2024

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 8 of 8 quarters
    “…S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing…”

    $31.0M lobbying spend in 2024, all issuesQ4 2024 filing

  2. America's Health Insurance Plans Inc (ahip) 8 of 8 quarters
    “…S. 79 - Interagency Patent Coordination and Improvement Act of 2023 - Sen. Durbin, Richard - prescription drug patenting S. 113 - Prescription Pricing for the People Act of 2023 - Sen. Grassley, Chuck - PBM transparency S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 - Sen. Cantwell, Maria - PBM…”

    $11.8M lobbying spend in 2024, all issuesQ4 2024 filing

  3. Amgen Inc 8 of 8 quarters
    “S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 . S. 1250 Drug-price Transparency for Consumers Act S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve…”

    $11.6M lobbying spend in 2024, all issuesQ4 2024 filing

11 more organizations, every filingPROUpgrade

Organizations that named S. 79 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

5 actions · newest first
  1. Mar 1, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.
  2. Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
  3. Feb 9, 2023Committee on the Judiciary. Ordered to be reported without amendment favorably.
  4. Jan 25, 2023Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
  1. Jan 25, 2023Introduced in Senate